Shanghai RAAS: Controlling shareholder continues share increase

Shanghai RAAS Blood Products (SZSE:002252) announced that its controlling shareholder, Haiyingkang (Qingdao) Medical Technology, continues to increase its stake in the company. As of April 7, 2025, Haiyingkang directly holds 1,438,154,552 shares, representing 21.67% of the company's total share capital. Additionally, Haiyingkang controls the voting rights attached to 437,069,656 shares (6.58% of total shares) through a voting rights proxy from Grifols, S.A., resulting in total control over 1,875,224,208 shares, representing 28.25% of Shanghai RAAS's total share capital. Since the initial announcement of the increase plan, Haiyingkang has acquired 36,618,700 shares through the Shenzhen Stock Exchange, amounting to 0.55% of the total share capital, with a total investment of CNY25,303.18 million (excluding transaction costs). The planned increase remains ongoing within a range of CNY250 million to CNY500 million.